The stock's rise snapped a five-day losing streak.
Fintel on MSN1d
Morgan Stanley Upgrades Gilead Sciences (GILD)Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...
Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...
Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for ...
The global biotechnology industry market size is projected to expand from USD 483.0 billion in 2024 to USD 546.0 billion by 2025, reflecting ...
The global biotechnology industry market size is projected to expand from USD 483.0 billion in 2024 to USD 546.0 billion by ...
Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...
This report provides detailed analysis of the current state of CAR-T cell therapies and the broader CAR-T industry landscape.Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapy Market - ...
BofA Securities has recently resumed Gilead Sciences Inc (GILD) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had initiated ...
In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other stocks Jim Cramer talked about. Jim Cramer, host of Mad Money, recently shared ...
Gilead Sciences, Inc. (GILD) Stock Sees Market Value Hit $117.09 billion: What Are the Implications?
BofA Securities has recently resumed Gilead Sciences, Inc. (GILD) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback